Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.

<h4>Background</h4>Some clinical studies have demonstrated that the proton pump inhibitor (PPI) could decrease clopidogrel platelet response and increase major adverse cardiovascular events (MACE) in white or black subjects. However, that remains to be determined in Chinese patients. In...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jian-Jun Zou, Shao-Liang Chen, Jie Tan, Ling Lin, Ying-Ying Zhao, Hai-Mei Xu, Song Lin, Juan Zhang, Hong-Wei Fan, Hong-Guang Xie
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/cc4d41f16a17445982952b04cb94cf8e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cc4d41f16a17445982952b04cb94cf8e
record_format	dspace
spelling	oai:doaj.org-article:cc4d41f16a17445982952b04cb94cf8e2021-11-18T08:38:27ZIncreased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.1932-620310.1371/journal.pone.0084985https://doaj.org/article/cc4d41f16a17445982952b04cb94cf8e2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24416326/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>Some clinical studies have demonstrated that the proton pump inhibitor (PPI) could decrease clopidogrel platelet response and increase major adverse cardiovascular events (MACE) in white or black subjects. However, that remains to be determined in Chinese patients. In this study, we sought to determine whether there could be an increased risk for developing MACE after concomitant use of dual antiplatelet therapy (DAT) and a PPI in Chinese patients treated with percutaneous coronary intervention (PCI) and stenting.<h4>Methods</h4>This study was a 5-year, single-center, retrospective cohort analysis of eligible patients (n = 6188) who received DAT and a PPI concomitantly (defined as PPI users) before discharge and/or 12-month follow-up after discharge as compared with those who received DAT alone (also defined as non-PPI users, n = 1465). The incidence of recurrent MACE, such as myocardial infarction (MI), definite stent thromboses (ST), or cardiovascular death, was compared between the PPI users and non-users.<h4>Results</h4>PPI users had a significantly higher incidence of the MACE than non-users (13.9% vs. 10.6%; adjusted HR: 1.33; 95% CI: 1.12 - 1.57, P = 0.007). Stratified analysis revealed that concurrent use of DAT and a PPI was associated with a significantly increased risk for developing ST compared with DAT alone (1% vs. 0.4%; adjusted HR: 2.66, 95% CI: 1.16 - 5.87, P = 0.012). However, there were no significant differences in the risk of MI, cardiovascular death and other adverse events, regardless of combination of clopidogrel and a PPI.<h4>Conclusions</h4>The study further suggests that concomitant use of DAT and a PPI may be associated with an increased risk for developing MACE, in particular definite ST, in Chinese PCI patients after discharge as compared with use of DAT alone.Jian-Jun ZouShao-Liang ChenJie TanLing LinYing-Ying ZhaoHai-Mei XuSong LinJuan ZhangHong-Wei FanHong-Guang XiePublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 1, p e84985 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jian-Jun Zou Shao-Liang Chen Jie Tan Ling Lin Ying-Ying Zhao Hai-Mei Xu Song Lin Juan Zhang Hong-Wei Fan Hong-Guang Xie Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
description	<h4>Background</h4>Some clinical studies have demonstrated that the proton pump inhibitor (PPI) could decrease clopidogrel platelet response and increase major adverse cardiovascular events (MACE) in white or black subjects. However, that remains to be determined in Chinese patients. In this study, we sought to determine whether there could be an increased risk for developing MACE after concomitant use of dual antiplatelet therapy (DAT) and a PPI in Chinese patients treated with percutaneous coronary intervention (PCI) and stenting.<h4>Methods</h4>This study was a 5-year, single-center, retrospective cohort analysis of eligible patients (n = 6188) who received DAT and a PPI concomitantly (defined as PPI users) before discharge and/or 12-month follow-up after discharge as compared with those who received DAT alone (also defined as non-PPI users, n = 1465). The incidence of recurrent MACE, such as myocardial infarction (MI), definite stent thromboses (ST), or cardiovascular death, was compared between the PPI users and non-users.<h4>Results</h4>PPI users had a significantly higher incidence of the MACE than non-users (13.9% vs. 10.6%; adjusted HR: 1.33; 95% CI: 1.12 - 1.57, P = 0.007). Stratified analysis revealed that concurrent use of DAT and a PPI was associated with a significantly increased risk for developing ST compared with DAT alone (1% vs. 0.4%; adjusted HR: 2.66, 95% CI: 1.16 - 5.87, P = 0.012). However, there were no significant differences in the risk of MI, cardiovascular death and other adverse events, regardless of combination of clopidogrel and a PPI.<h4>Conclusions</h4>The study further suggests that concomitant use of DAT and a PPI may be associated with an increased risk for developing MACE, in particular definite ST, in Chinese PCI patients after discharge as compared with use of DAT alone.
format	article
author	Jian-Jun Zou Shao-Liang Chen Jie Tan Ling Lin Ying-Ying Zhao Hai-Mei Xu Song Lin Juan Zhang Hong-Wei Fan Hong-Guang Xie
author_facet	Jian-Jun Zou Shao-Liang Chen Jie Tan Ling Lin Ying-Ying Zhao Hai-Mei Xu Song Lin Juan Zhang Hong-Wei Fan Hong-Guang Xie
author_sort	Jian-Jun Zou
title	Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
title_short	Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
title_full	Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
title_fullStr	Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
title_full_unstemmed	Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
title_sort	increased risk for developing major adverse cardiovascular events in stented chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/cc4d41f16a17445982952b04cb94cf8e
work_keys_str_mv	AT jianjunzou increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT shaoliangchen increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT jietan increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT linglin increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT yingyingzhao increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT haimeixu increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT songlin increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT juanzhang increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT hongweifan increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor AT hongguangxie increasedriskfordevelopingmajoradversecardiovasculareventsinstentedchinesepatientstreatedwithdualantiplatelettherapyafterconcomitantuseoftheprotonpumpinhibitor
_version_	1718421527792189440

Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.

Ejemplares similares